Givosiran · GIVLAARI
RNA / oligonucleotide
Evidence outlook
Approved: Acute Hepatic Porphyria
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Treatment of acute hepatic porphyria
- Givlaari: acute hepatic porphyria in adults
- Acute hepatic porphyria in adults and adolescents aged 12 years and older
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03338816 NCT03338816 · Acute Hepatic Porphyria This was a randomized, quadruple-blind, placebo-controlled trial with 94 participants, including 46 assigned to givosiran and 48 to placebo. The hard clinical primary endpoint—annualized porphyria attacks—was met: the rate was 3.22 with givosiran versus 12.52 with placebo, with a rate ratio of 0.26 (95% CI 0.16–0.41; p<0.0001). Registry: NCT03338816 | 3 | Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) (6 months) 2019-01-31 | Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP) (6 months): Placebo 12.52 annualized attack rate (95% CI 9.35 to 16.76) | Givosiran 2.5 mg/kg 3.22 annualized attack rate (95% CI 2.25 to 4.59) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.